Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Recce Pharmaceuticals Ltd. currently holds a patent portfolio with 1 pending office action in the Chemistry & Materials technology area. This single active matter is being reviewed by 1 distinct examiner, HUHN, RICHARD A, who is also the busiest examiner with 1 busiest examiner pending action. The prosecution is concentrated within 1 distinct art unit, reflecting a narrow technical focus for the company's current USPTO filings.
Practitioners should recognize that having 1 pending office action under 1 distinct examiner creates a singular focus for the portfolio's current efforts. HUHN, RICHARD A is the sole individual responsible for the 1 busiest examiner pending action, meaning his specific preferences will dictate the immediate results in the Chemistry & Materials area. The matching count of 1 pending office action and 1 distinct examiner within 1 distinct art unit simplifies the tracking of deadlines and examiner interviews. However, this lack of examiner variety means the company cannot test different arguments across multiple files. The outcome of this 1 pending office action will define the company's standing at the USPTO for this technology area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUHN, RICHARD A | 1 | 67.2% | +5.5% |
| Art Unit | Apps |
|---|---|
| 1764 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17871164 | PROCESS FOR PREPARATION OF BIOLOGICALLY ACTIVE COPOLYMER | HUHN, RICHARD A | 1764 | §103 | Final Rejection | 49d | Pending | Jul 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRecce Pharmaceuticals Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Richard A Huhn has the most, with 1 of Recce Pharmaceuticals Ltd.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.